46 results about "Exogenous growth" patented technology

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

A versatile compartmentalized cell culture device, with a selectively permeable membrane separating the compartments, provides many attributes relative to traditional devices. It can be configured for high-density cell culture, co-culture, and sample dialysis while rolling or standing still. It can also be configured for continuous movement of liquid between compartments. The wide combination of attributes not found in other membrane based cell culture and bioprocessing devices includes more cell capacity, more cell secreted product capacity, higher cell and product density, increased medium capacity, minimized use of exogenous growth factors, compatibility with standard cell culture equipment and protocols, increased scale up efficiency, capacity to function when rolling or standing still, capacity for perfusion without the need for pumps, and more efficient sample dialysis.

Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

A composition including delipidated, decellularized adipose tissue and delipidated, decellularized fascial tissue is provided. The composition may further include exogenous tissuegenic cells, an exogenous growth-inductive substance, and/or a carrier. The composition is suitable for implantation into a living body in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, wound care procedures or other procedures of regenerative medicine. A method of preparing an acellular soft tissue-derived matrix from adipose tissue and fascial tissue is also provided. The method involves preparing a delipidated, decellularized adipose-derived matrix by delipidizing the adipose tissue and decellularizing the adipose tissue; preparing a delipidated, decellularized fascia-derived matrix by delipidizing the fascial tissue and decellularizing the fascial tissue; and combining the delipidated, decellularized adipose-derived matrix and the delipidated, decellularized fascia-derived matrix to produce said acellular soft tissue-derived matrix. The resulting Acellular soft tissue-derived matrix may be partially dried, substantially dried, or not dried.

The present invention provides methods and DNA constructs for the genetic engineering of plant cells to produce plants which produce substantially seedless fruit in the absence of exogenous growth factors (auxins or cytokinins) and in the absence of pollination. The substantially seedless fruits produced by the methods described herein are about the size of wildtype seeded fruit (or somewhat larger) and these fruits are equal to or superior to the wildtype seeded fruit with respect to solid content and flavor. The seedless fruits of the present invention are produced in transgenic plants which contain and express auxin or cytokinin biosynthetic genes, e.g., tryptophan oxygenase or isopentenyl transferase coding sequences expressed under the regulatory control of GH3 or AGL promoter sequences directing preferential or tissue specific expression of a downstream gene in the ovaries or developing fruit.

The invention relates to a method for obtaining tissue engineering cartilage through directionally inducing bone-marrow mesenchymal stem cells (BMSCs). At present, a large amount of exogenous growth factors and culture in vitro are needed before culturing the BMSCs and the cartilage cells in vivo to promote the differentiation of the BMSCs towards the cartilage cells. The method comprises the following steps of: mixing the sub-cultured P3-generation BMSCs, the cartilage cells and a large extracellular matrix aggregate (cell brick), resuspending the mixture into a platelet rich plasma to prepare a cell compound of the sub-cultured P3-generation BMSCs, the cell brick and the platelet rich plasma, injecting the compound into the skin on the back of a nude mice when the compound condenses gradually, and culturing to obtain the new tissue engineering cartilage. The completely biological and injectable tissue engineering cartilage is obtained on the basis of coculturing the BMSCs and the cartilage cells. The differentiation of the BMSCs towards the cartilage cells can be kept stably, the hypertrophy of the tissue engineering cartilage in vivo can be inhibited effectively, and the defects in the background art can be overcome.

The invention provides an expansion system in vitro for hematopoietic stem/progenitor cells used for expanding human umbilical cord blood in vitro of soluble fusion protein Dll1-RGD (Hdll1-RGD) of notch ligand of a vascular endothelial cell target. The effective expansion system in vitro is formed by taking human umbilical vein endothelial cells as supporting cells of a cultivation system, jointly applying exogenous growth factors SCF, TOP, FL, IL-6, IL-3 and own developed hDLL1-RGD, and co-cultivating with the hematopoietic stem/progenitor cells. According to the expansion system, the hDll1-RGD target is combined to the surface of a human umbilical vein endothelial cell, activated stimulation aiming at a notch receptor is provided for the hematopoietic stem cells, and self-renewal and propagation of the hematopoietic stem cells are maintained, so that a satisfactory expansion effect and favorable implantation capacity are obtained.

A method of retaining growth factors on a substrate for release at a treatment region comprises immobilizing an antagonist of the growth factor on a substrate and binding of the growth factor to the antagonist. In one aspect, the substrate is provided on a bioimplant. The resulting bioimplant allows for activity of the growth factor to continue at the region of implantation. According to the method of the invention, exogenous growth factors can be used to stimulate the repair of various tissues and organs at the site requiring repair, and be protected from inactivation, sequestration or degradation. The invention also provides bioimplants and methods of delivering growth factors.

A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4/5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.

The invention relates to the field of regeneration and repair of tissues and organs and in particular relates to a method for preparing a tendon repair material and provides a novel path for tendon defect repair. The tendon repair material disclosed by the invention is prepared by binding animal-derived decellularized achilles tendon material and specific tendon seed cells. The achilles tendon material selectively remains various expected beneficial components contributing to tendon regeneration while eliminating immunogenicity of heterologous tissues, while the seed cells are in-vitro controllable induced receptor tendon cells of exogenous growth factors. According to the combination of the achilles tendon material and the seed cells, an effect of regenerating tissue-engineered tendons iseffectively achieved, the clinical applicability is high, and the tendon repair material is preferentially but not limited to be applied to tendon repair.

The invention relates to the technical field of biomaterial, and relates to a preparation method for a nanometer allograft decalcified bone matrix material DBM for bone graft. The preparation method comprises the following steps: 1) making a fresh allograft bone into DBM bone pieces conventionally by adopting an improved Urist method; 2) placing the DBM bone pieces into a liquid nitrogen refrigerating grinder to pre-grind, so as to obtain DBM powder; and 3) preparing the nanometer DMB, that is, placing the DBM powder in an ultrathin powder grinder, adding proper distilled water, grinding the DBM powder completely at a temperature of between 17 and 25 DEG C, treating the obtained homogenate after grinding by high-speed centrifugation, removing supernatant, then obtaining the nanometer DBM, and finally disinfecting the nanometer DBM for standby after molding and drying. The preparation method is convenient and uses the allograft bone as a raw material, so the material is easy to obtain; because the DBM prepared by the method is of a nanometer structure, the nanometer DBM can be used as a bone graft substitute, has good biocompatibility, can be used as a favorable carrier for exogenous growth factors such as bone morphogenetic protein and the like for promoting osteanagenesis, and has favorable capability for promoting osteanagenesis.

The invention relates to the technology field of biological materials and discloses an allogeneic nano-decaicified bone matrix material nano-DBM for bone graft. The nano-DBM is prepared by a fresh allogeneic bone, and the preparation method is as follows: 1) the fresh allogeneic bone is prepared into a DBM bone block by adopting the improved Urist method according to the conventional way; 2) the DBM bone block is arranged in a liquid nitrogen freezing crushing machine for pre-crushing, thereby obtaining DBM powder; 3) the nano-DBM is prepared: the DBM powder is arranged in an ultrafine grinding smashing machine, appropriate distilled water is added, the full grinding is carried out at 17 DEG C to 25 DEG C, homogenate obtained after the grinding is centrifugalized at high speed, supernatant liquid is abandoned, the nano-DBM is obtained, and the nano-DBM is ready for use after shaping and drying. The nano-DBM takes the allogeneic bone as raw materials, the obtainment of the materials is easy; the nano-DBM can be shaped freely; the nano-DBM has good biocompatibility as the bone graft substitute material due to the nano-structure and also has the good ability as a good carrier of exogenous growth factors for promoting the bone regeneration, such as a bone morphogenetic protein, and the like.

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and/or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

A versatile compartmentalized cell culture device, with a selectively permeable membrane separating the compartments, provides many attributes relative to traditional devices. It can be configured for high-density cell culture, co-culture, and sample dialysis while rolling or standing still. It can also be configured for continuous movement of liquid between compartments. The wide combination of attributes not found in other membrane based cell culture and bioprocessing devices includes more cell capacity, more cell secreted product capacity, higher cell and product density, increased medium capacity, minimized use of exogenous growth factors, compatibility with standard cell culture equipment and protocols, increased scale up efficiency, capacity to function when rolling or standing still, capacity for perfusion without the need for pumps, and more efficient sample dialysis.

The invention relates to the technical field of planting, and in particular relates to a method for avoiding dormancy of seeds of Paris polyphylla var.chinensis by using an exogenous growth regulatingagent. The method comprises the following steps: immersing the seeds into an exogenous growth regulating agent solution for 48 h, performing cleaning, performing disinfection, using double-layered degreasing cotton gauze as a bud bed, and performing germination for 90 days in a manual climatic box at temperature of 25 DEG C under dark condition. According to the method provided by the invention,the germination effects of the seeds of the Paris polyphylla var.chinensis are as follows: GA3 > 2,4-D > 6-BA > KMnO4 > CK > alpha-NAA, and when a best combination of 500 mg/L GA3, 0.3% KMnO4 and 10 mg/L 6-BA is used to process the seeds of the Paris polyphylla var.chinensis, the germination rate and germination force of the seeds can be significantly improved, the germination rate of the seeds can reach 91.33%.

The invention provides an economic, simple and convenient lung organ culture method and an experimental model, and relates to the technical field of biology. The method comprises the following steps: marking a transgenic mouse with pulmonary epithelial cells by using GFP (Green Fluorescent Protein), sorting the pulmonary epithelial cells and interstitial cells by using a flow cytometry, then co-culturing the sorted lung epithelial cells and mesenchymal cells in an upper-layer small chamber and a lower-layer small chamber divided by Transwell, and promoting the epithelial cells in the upper-layer small chamber to grow and develop into lung organs by using growth factors and biological components secreted by the mesenchymal cells in the lower-layer small chamber. According to the method of the invention, the natural growth environment and mode of in-vivo cells are simulated, and the lung bronchial organ can be obtained under the condition that exogenous growth factors are not added. The mouse lung organ can be used as the experimental model, and can be used for research on lung development process, cell differentiation, lung toxicology, drug screening, organ regeneration and transplantation, etc.

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

The invention relates to the technical field of cutting planting of chrysanthemum, and discloses a cutting seedling raising method for chrysanthemums. A nursing solution and an exogenous growth regulator are jointly used to process cutting slips, wherein auxin induces the formation of a cutting slip root base, meanwhile, adjusts the physiological state of the plant cutting slips, promotes the synthesis of chlorophyll, adjusts the content of soluble sugar, and increases the accumulation of soluble protein, so that the rooting and growth of the cutting slips are facilitated; and with the joint process on the cutting slips, the rooting and growth of the cutting slips is facilitated, the differentiation of calluses is improved, the proliferation of buds is promoted, and the cultivation of strong seedlings is facilitated. According to the invention, the interaction effect of the exogenous growth regulator is studied, and the matrix component is proportioned, so that the survival rate and the uniformity of the cutting seedlings can be improved, and the resistance to diseases and environment changes can also be enhanced.